

**Midbrain Mutiny: The  
Picoeconomics and  
Neuroeconomics of  
Disordered Gambling**

Economic Theory and  
Cognitive Science

Don Ross, Carla Sharp,  
Rudy Vuchinich, and  
David Spurrett

A Bradford Book  
The MIT Press  
Cambridge, Massachusetts  
London, England

© 2008 Massachusetts Institute of Technology

All rights reserved. No part of this book may be reproduced in any form by any electronic or mechanical means (including photocopying, recording, or information storage and retrieval) without permission in writing from the publisher.

MIT Press books may be purchased at special quantity discounts for business or sales promotional use. For information, please e-mail [special\\_sales@mitpress.mit.edu](mailto:special_sales@mitpress.mit.edu) or write to Special Sales Department, The MIT Press, 55 Hayward Street, Cambridge, MA 02142.

This book was set in Palatino by SNP Best-set Typesetter Ltd., Hong Kong, and was printed and bound in the United States of America.

Library of Congress Cataloging-in-Publication Data

Midbrain mutiny : the picoeconomics and neuroeconomics of disordered gambling : economic theory and cognitive science / Don Ross . . . [et al].  
p. ; cm.

Includes bibliographical references and index.

ISBN 978-0-262-18265-2 (hardcover : alk. paper)

1. Compulsive gambling. 2. Motivation (Psychology). 3. Reward (Psychology).  
4. Choice (Psychology). 5. Neuroeconomics. 6. Economics. 7. Cognitive science.

I. Ross, Don, 1962-.

[DNLM: 1. Gambling. 2. Behavior, Addictive. 3. Cognitive Science.

4. Economics. WM 190 M627 2008]

RC569.5.G35M53 2008

616.85'841—dc22

2007034671

10 9 8 7 6 5 4 3 2 1

# Index

- Abstinence, 86, 151, 156, 159, 180, 221, 227, 231
- Acceptance and commitment therapy, 198
- Addiction (general), 2, 4, 146, 155–157, 160, 163, 174–175, 192, 200, 206, 228
- diagnostics of, 164
- Addictive gambling (AG), 117–119, 121–122, 140–141, 144, 149–153, 157–158, 161, 163–170, 177, 200–203, 205–208, 210–211, 212, 215, 216–219, 225–226, 228–230, 233–234, 240, 242, 246–248
- Adrenocorticotrophic hormone, 158
- Agrawal, N., 7
- Ahmed, S., 167
- Ainslie, G., 14, 35, 47–48, 51, 62–63, 65–67, 69, 71–72, 75, 77, 82, 83, 84, 90–91, 102, 127–128, 219, 221, 223, 230–231, 236–239, 242, 244, 246
- Herrnstein-Ainslie model, 236
- Akers, R., 4–5
- Alcohol, 1, 4, 30, 69, 73, 77–79, 84, 86, 99, 112–115, 118, 146–147, 149, 156, 159, 163, 207–209, 212, 222, 226–228, 234, 242, 245
- abuse, 1, 2, 44, 49–50, 52, 66, 81, 92, 102, 105, 152, 155, 161, 163, 171–172, 177, 180, 188, 213, 223, 226, 228, 234
- binge drinking, 223, 226, 242
- comorbidity, 185, 187
- Alessi, S., 107
- Allen, A., 187
- American Psychiatric Association (APA), 2–3, 32–33, 43, 179
- Amit, D., 9
- Amphetamine, 149, 163, 172
- Amygdala, 8–9, 134–135, 146, 156, 186, 191
- central nucleus, 157
- illustration, 134
- Anderson, S., 100
- Andreoli, M., 191–192
- Animal research, 51, 54–55, 57, 61, 63, 69, 74, 87–88, 90–92, 107, 125, 139, 141, 151, 153, 163–164, 215, 223, 241, 243–244
- Anterior cingulate cortex (ACC), 132, 137, 139, 152, 156, 187, 200
- rostral, 9
- ventral, 173
- Anthropology, 225
- Anxiety, 184–185, 187
- Appetite, 70, 82, 127–128, 138, 147, 151, 155, 163–164, 167, 211, 223, 241
- Attention, 66, 143–144, 171, 174, 178, 192, 199, 219
- attention-switching, 152–153
- Attention deficit hyperactivity disorder (ADHD), 185–186, 189, 193–194
- Atypical antipsychotics, 181, 185, 188–190, 193
- Autism, 7
- Babor, T. F., 4
- Baez, C., 197
- Baik, J., 151
- Baird, J. R., 198
- Bargh, J., 113
- Baron, E., 38, 113
- Barratt, E., 106
- Barratt Impulsivity Scale (BIS and BIS-II), self report of impulsivity, 106, 108
- Bartow, A., 125–126, 137, 150–151, 153–154

- Basal ganglia, 132, 173  
 Basolateral area, 157  
 Baunez, C., 192  
 Bechara, A., 98, 151–152  
 Becker, G., 6, 49–50, 76, 243–244  
 Behavioral economics (BE), 6, 41–43, 45–47, 91, 95, 106, 114, 117–118, 130, 142, 159–160, 165, 170, 180, 193–194, 201, 204, 219  
 Behavioral therapy, 217, 226  
 Behaviorism, 197–198, 220, 226, 231–232, 234, 241  
 Beninger, R. J., 191  
 Bergh, C., 169–170  
 Berns, G., 12, 125, 138–139  
 Berridge, K., 113, 139, 141–143  
 Bickel, W., 44, 61, 99, 102, 107, 153  
 Billieux, J., 107  
 Bipolar disorder, 182, 186, 193–194  
 Bishop, M., 195–196  
 Bjork, K., 175  
 Black, D. W., 185, 189  
 Blair, R., 8  
 Blanco, C., 177, 183, 187, 218–219  
 Blaszczyński, A., 38–39, 107, 194, 196–197, 228–229  
 Bloom, F., 146  
 Blume, S., 38  
 Bohus, M., 193  
 Boisvert, J., 196  
 Bossaerts, P., 120, 127, 130, 140, 143, 166  
 Boulenguez, P., 186  
 Boyer, M., 111  
 Brain damage, 89, 139, 141, 157, 209, 245  
 Brand, M., 97, 110  
 Breen, R., 183, 187  
 Breiter, H., 169  
 Brin, M., 232  
 Bunzeck, N., 166  
 Bupropion (Wellbutrin), 185, 189  
 Burgess, G., 110  
  
 Camerer, C., 45  
 Canadian Problem Gambling Index (CGI), 39, 118  
 Caplin, A., 238–239  
 Carbamazepine, 186  
 Carnes, Patrick, 213  
 Carroll, M., 44  
 Casarella, T., 105  
 Casinos, 20–23, 26, 46, 80–81, 84–85, 105, 112–113, 171, 173, 175, 195–197, 202–204, 210, 215–216, 223, 228, 243–244, 246  
     casino games, 21, 113, 234  
 Catania, A., 54  
 Cavedini, P., 171, 174  
 Cerebral cortex, 154  
 Cerebrospinal fluid (CSF), 169  
 Ceschi, G., 107  
 Chaloupka, F., 44  
 Chambers, R. A., 150–151, 174–175, 185, 189  
 Changeux, J. P., 109  
 Chao, L., 110  
 Chapman, G., 74  
 Chiamulera, C., 192  
 Chiu, Y. C., 97  
 Chung, S., 54, 90  
 Churchland, P., 9  
 Cingulate cortex, 163  
 Cingulate gyrus, 152  
 Citalopram (Celexa), 183  
 Clark, A., 11, 247  
 Classical conditioning, 92, 127–128  
     conditioned reinforcers (CR), 127–128  
     conditioned stimuli (CS), 127–128, 142  
 Cleckley, H., 8  
 Clomipramine, 182–183, 186  
 Cloud, W., 180  
 Cocaine, 99, 147, 149, 151, 153, 159, 163, 167, 207–208, 212, 219  
     abuse, 103, 108, 111, 162–163, 172–173, 191, 208, 219  
     science, 123, 125, 220, 242, 244, 246  
 Cognition  
     distortions, 72  
     executive functioning, 109–111, 198–199  
     framing, 242–246  
     global functioning, 189  
     impairment, 108–111, 115, 117, 152–153, 156, 159, 172, 174  
 Cognitive behavioral therapy (CBT), 194–200, 202, 209, 226, 233  
     cognitive distortions, 194–197, 202, 208–209  
     efficacy, 196  
     techniques, 195, 202  
 Cohen, C., 2, 4  
 Cohen, J., 126, 156  
 Collins, P., 23, 25–26  
 Comings, D., 177

- Committee on the Social and Economic Impact of Pathological Gambling 1999, 190
- Comorbidity, 39–40, 177, 182–186, 189–190, 192–194, 228
- Competitive market model, 243–244
- Computational learning model, 9–10, 126, 220
- Consumption, 44, 49, 72, 85, 93, 98–99, 102–104, 109–110, 112, 155–156, 158–161, 167, 208, 211, 214, 220–221, 225, 230–231, 245
- Cortical areas, 132, 138, 162, 225–226 inhibition, 175, 207
- Cost and benefit, 44–46, 70, 80
- Cox, W., 111
- Craving, 67, 92, 128, 154, 156, 173–174, 241
- Crockford, D., 39, 173, 184
- Cross, D., 100
- Cubitt, R., 81
- Cunningham-Williams, R., 39
- Curtin, J., 108
- Daly, M., 113
- D-amphetamine, 172
- Dannon, N., 184–185, 188–189
- Dannon, P., 39
- Daw, N., 125–126, 129, 143
- Dayan, P., 9, 129
- Dean, M., 238–239
- Decision making, 51, 53, 62–63, 74–75, 77–79, 88, 91, 93–95, 131, 199, 235, 237–238, 244
- DeGrandpre, R., 44
- Dehaene, S., 109
- De La Gandara, J. J., 183, 187
- Dell’Osso, B., 187
- Denburg, N., 98
- Dennett, D., 10–11, 154
- Depakote, 186
- Dependency (general), 3, 19, 118, 164, 187, 194
- Depression, 19, 29, 177, 187, 194
- Deprivation, 91–92, 103, 160
- Developmental stages, 98, 175 adolescents, 85, 96, 99, 151, 175, 216–217 elderly, 85, 151, 221
- de Wit, H., 114
- Diagnostic and Statistical Manual of Mental Disorders (DSM), 2–4, 13, 32–34, 36–38, 65, 82, 103, 118–119, 168, 176, 179–180, 186, 196, 200–202, 205–206, 218–219, 229
- Diagnostic Interview for Gambling Severity (DIGS), 39
- Dias, R., 110
- Dickerson, E., 38, 111
- Dickinson, A., 113, 150, 157, 191
- Disanalogy, 207–209, 215
- Discounting, 91, 96–103, 105–107, 113, 235–237, 244–245  $\beta$ - $\delta$  (beta delta), 93, 235–236, 238 delay discounting task (DDT), 107–108 delayed, 99–103, 105, 112–114 exponential, 58–60, 75, 88, 235–236 functions, 102, 236–237, 239 hyperbolic, 56–60, 62–63, 65, 67, 70–71, 73, 75, 86–90, 92–94, 100, 120, 128, 214, 222, 225, 227, 235–236, 238, 241, 244–245 hyperbolically reward bundle, 68–69, 102, 222, 248, 221–223, 239, 244–246, 248 probability, 98, 100–101, 113–114 subadditive discounting model, 89–90, 240, 242, 244, 246 time-discounted sum, 125
- Disordered gambling (DG), 14–15, 18, 43–45, 52–53, 58, 61, 65, 82–86, 89, 94–95, 98–99, 102–107, 109, 111–112, 115, 117, 119–120, 122, 150, 166, 178, 190, 200–202, 204–205, 206–210, 214, 218–222, 225–226, 228–230, 233–235, 240, 246–248 criterion, 34, 36–39, 41, 201
- Disulfiram, 66
- Dixon, M., 104, 111
- Dodd, M., 190–191
- Dom, G., 108
- Dopamine, 125, 135, 139, 142, 146, 148, 150–151, 153–155, 160, 167, 169–170, 174, 181, 186 agonists, 190–191, 228 concentration, 136, 138, 147, 149, 155–156, 160, 169, 171, 187–188, 221 learning, 143, 152 receptor (D1), 154 receptor (D2), 135, 150, 154, 189–192, 176–177 receptor (D3) antagonist (SB-277011), 192 response, 151, 156, 169

- Dopamine reward system, 16, 125–129, 131, 137, 141–143, 150, 152–154, 157, 166–167, 170–172, 176, 179, 189, 193, 200, 205–206, 215, 224, 230–231, 233–234, 236–237, 239, 241, 246, 247  
dysfunction, 118  
NAcc and caudate nucleus, 144  
regulation of, 157  
Dorris, M., 173–174  
Dorsal striatum, 133  
illustration, 134  
Dorsolateral frontal cortex, 245  
Dorsolateral prefrontal cortex (DLFPC), 9, 132–133, 173–174  
Du, W., 101  
Dumont, E., 151, 196  
Durstewitz, D., 141  
Düzel, E., 166
- Echeburúa, E., 197  
Economic analysis, 44, 46, 242–243, 246  
Edelman, G., 12  
Eisen, S., 176  
Eklundh, T., 169  
El-Guebaly, N., 39, 184  
Ellen, J., 115  
Enkephalins, 135  
Epinephrine, 171  
Escitalopram (Lexapro), 184  
Evans, C., 98  
Evenden, J., 44, 219–221, 224, 248  
Everitt, B., 150, 157, 191  
Evolution, 131–132, 139, 154–155, 166, 224–225, 232–233  
phylogeny, 216  
Experiential Discounting Task (EDT), 114  
Eysenck Impulsivity Questionnaire, 107  
Eysenck Impulsivity Scale, 104
- Fadardi, J., 111  
Farah, M., 245  
Feigelman, W., 39  
Fellows, L., 245  
Fernandez-Juricic, E., 100  
Fernandez-Montalvo, J., 197  
Ferris, J., 39  
Field, M., 111  
Financial consequences, 206–207, 209  
Financial factors, 64, 221  
Flavell, J. H., 198  
Fluoxetine (Prozac), 137  
Fluvoxamine (Luvox), 182–184, 186–187  
Fonagy, P., 8  
Food and Drug Administration (FDA), 181  
Frank, R., 74  
Frankova, A., 196–197  
Frederick, S., 88  
Frontal cortex, 131, 146, 155, 225  
Frontal lobes, 109–110, 171  
Fulkerson, J., 175  
Fuster, J., 109
- GABA, 133, 135, 146–148, 150, 188, 221, 241  
GABA-A, 172  
Gaboury, A., 195  
Galanter, M., 115  
Gallistel, C., 127  
Gamblers Anonymous, 41  
Gamblers' Beliefs Questionnaire, 107  
Gambler's fallacy, 247, 228  
Gambling Passion Scale, 107  
Game theory, 63–64, 75, 89  
Garavan, H., 111, 152, 153  
Gehring, W., 248  
Genetics, 157–158, 162–163, 175–177, 229, 248  
allele, 176–177  
mutant mouse, 157  
vulnerability, 175–177, 229  
Gerlach, K., 227  
Gerstein, D., 218  
Gibbon, J., 127  
Giordano, L., 103  
G-learning, 127–129, 144  
Glicksohn, J., 97  
Glimcher, P., 12, 63, 125, 154, 173–175, 219, 237–240, 245  
Glucocorticoid, 158  
Glutamate, 147–148, 150–151, 153–155, 160, 170, 172, 177  
AMPA, 151  
NMDA, 151  
Goldstein, R., 155–156, 165  
Gorelova, N., 148  
Gosling, S., 107, 193  
Goudriaan, A., 169, 171  
Grabowecky, M., 109  
Grace, R., 156  
Granfield, R., 180  
Grant, J., 181, 183–185, 187–190, 193  
Gray, P., 19, 151

- Green, L., 54–55, 66, 90, 100, 101, 103–104, 244–245
- Griffiths, M., 195, 214
- Grosset, K. A., 191
- Grossman, M., 44
- Guastello, B., 69
- Gul, F., 94, 236, 238–240, 242–246
- Gulledge, A., 148
- Güntürkün, O., 141
- Hacking, I., 161, 211
- Haendel, V., 102
- Hair, P., 99
- Hall, M., 105, 218
- Haller, R., 182
- Haloperidol, 185
- Halpern-Felsher, B., 115
- Hammerstein, P., 243–244
- Hampson, S., 99
- Hardoon, K., 195
- Hare, R., 8
- Harinder, A., 191
- Hariri, A., 237–238
- Harmsen, H., 98
- Hayes, S. C., 198
- Heather, N., 6
- Heil, S., 44
- Henningfield, J., 2, 4–5
- Heroin, 103, 118, 150, 207, 212, 227–228  
abuse, 96, 137, 219
- Herrnstein, R., 48, 51, 54, 65, 85–86, 90, 219–222, 230  
Herrnstein's theory, 67  
Herrnstein-Ainslie model, 236
- Hester, R., 111
- Heyman, G., 6
- Higgins, S., 44
- Hinterhuber, H., 182
- Hippocampus, 135, 156  
illustration, 134
- Hoch, S., 92
- Hollander, E., 181–183, 187, 193
- Holt, D., 103–104
- Hooper, C., 98
- Houston, A., 100
- Houthakker's axiom, 62
- Hybrid PE/NE model, 219, 230, 235
- Hypothalamus, 133, 135, 137, 158, 160, 164
- Ibáñez, A., 163, 176–177
- Ichikawa, J., 186–187
- Impaired response inhibition and salience attribution (I-RISA) model, 156–157, 162–163, 165, 169, 171–174, 176, 177–178, 180–181, 186–188, 190–191, 205, 207–208, 210, 225, 242
- Impulsivity, 3–4, 14, 43–44, 49, 53–54, 60, 62–63, 66, 75, 77–80, 85, 86, 89, 91, 94–95, 98–102, 104–108, 111–114, 117, 120, 128, 132, 138, 147, 153, 155–156, 160–161, 165, 174, 177, 179–180, 186, 193, 199, 211, 219–224, 226, 228–231, 233–236, 238, 240–242, 244–246
- Insula, 156, 174, 187, 200
- Internet, 211–213, 215
- Intimate relationships, 71–72, 84, 213–214
- Iowa Gambling Task (IGT), 96–98, 108, 114, 152, 171
- IQ, 108, 110
- Jacobs, E., 104
- Jaffe, D., 148
- Jaroni, J., 98
- Jarvik, M., 5
- Johnson, M., 61, 153
- Johnstone, E., 177
- Kable, J., 125, 237–238
- Kacelnik, A., 100
- Kagel, J., 45
- Kalivas, P., 153–154
- Kelc, M., 141
- Kelley, A., 154, 163
- Kelso, S., 232
- Kemish, K., 98
- Kerr, A., 100
- Kerszberg, M., 109
- Kertzman, S., 110–111, 174
- Kessler, R., 218
- Killeen, P., 127–128
- Kim, J., 218
- Kim, S., 181, 183–185, 188, 193
- King-Cassas, B., 126
- Kirby, K., 69, 90, 93, 99, 103
- Kirk, J., 91
- Kischka, U., 172
- Knight, R., 109–110
- Knutson, B., 139
- Koechlin, E., 109
- Koepp, M., 169
- Kollins, S., 102–103
- Koob, G., 146, 158, 174, 191, 203
- Kouneiher, F., 109

- Krishnan-Sarin, S., 102, 107  
 Kudadjie-Gyamfi, E., 113  
 Kyngdon, A., 113
- Laakso, A., 157  
 Ladd, G., 39, 193  
 Ladouceur, R., 194, 196, 199  
 Ladyman, J., 63, 75, 120–121  
 Laibson, D., 93, 93, 235–236  
 Larger later reward (LLR), 44, 53, 55–57,  
 60–61, 65–70, 83–85, 90, 99, 219, 231,  
 233, 235–236  
 Lau, M., 115  
 Le, D., 113  
 Learning, 9, 19, 125–130, 143, 150–157,  
 166, 194, 197, 199, 221  
 Lee, J. E., 227  
 Lejoyeux, M., 160–161  
 Le Moal, M., 158, 174  
 Leshem, R., 97  
 Lesieur, H., 38–39, 177  
 Leung, S. F., 44  
 Levine, H., 4  
 Levodopa, 191  
 Lieb, K., 193  
 Limbic system, 131–132, 171, 191,  
 235–236  
 Lindsley, O. R., 197–198  
 Lithium, 186  
 Locke, B., 180  
 Loewenstein, G., 45, 88–89, 91–94, 147,  
 160, 240–242, 244–246  
 Logue, A., 91  
 Long-range interests, 63, 71, 74, 164, 180,  
 188, 230–231, 234, 236, 242  
 Louie, K., 237–238  
 Lussier, J., 44  
 Lynam, D., 106
- Macaux, E., 90  
 MacKillop, J., 104, 107  
 Macroeconomics, 249  
 Macro model, 232  
 Madden, G., 44, 99, 102  
 Mahoney, M. J., 198  
 Marijuana, 96, 111, 212  
 Marks, I., 4  
 Marley, J., 104  
 Marsch, L., 61  
 Martin, E., 151–152  
 Martin-Soelch, C., 140, 152  
 Matching law, 48, 51–55, 57, 65, 120, 222  
 Maximization, 6, 16, 48–52, 61–62, 64, 81,  
 221–222, 225  
 May, J. C., 175  
 Mazur, J., 58, 90  
 McCarthy, G., 110  
 McClure, S., 94, 125–126, 143, 235–238,  
 240  
 McConaghy, N., 107, 196–197  
 McCulloch, W., 9  
 McNamara, J., 100  
 Medial prefrontal cortex (PFC), 163  
 illustration, 134  
 Medical model, 162, 210–211, 214  
 Meichenbaum, D., 198  
 Melamed, L., 110, 174  
 Melioration, 223, 227  
 Meltzer, H., 186–187  
 Memory, 150  
 episodic memory, 124, 154  
 impairment, 110–111, 240–241  
 working memory, 109, 151–152, 173  
 Mesolimbic system, 147, 155–156, 167,  
 171–173, 186, 188, 191, 225–226  
 Metacognition, 198–199, 209  
 Metacognitive therapy, 198–199, 233  
 Methadone, 96, 98  
 Meyer, G., 171  
 Microeconomics, 14, 17, 26, 48–49, 62–63,  
 94, 215, 232, 249  
 Midbrain reward system, 94, 109, 122,  
 130, 132, 144, 152, 156, 167, 181, 197,  
 225–226, 236–237  
 Mid-range interests, 71, 84–85  
 Miller, E., 109, 156  
 Millstein, S., 115  
 Mind-body dualism, 121  
 Mintzer, M., 96  
 Mirenowicz, J., 139  
 Mitchell, S., 101–102  
 MOA-A, 176  
 Modulation, 123, 172, 187  
 Molar model, 17, 92, 127, 230–231, 233–  
 241, 243–249  
 Molecular model, 21, 27, 42, 108, 231–241,  
 243, 245–248  
 Monetary rewards, 152, 175, 248  
 Montague, P. R., 8, 10, 12, 125–126, 129,  
 143  
 Monterosso, J., 69, 108, 223, 236–238  
 Mood dysfunction, 115, 146, 156, 192–194  
 Mood stabilizers, 181–182, 186, 189–190,  
 193



- Morphine, 163
- Moskowitz, J., 182
- Motivation, 20, 23, 52, 75, 88, 91, 139, 141–142, 145, 152–154, 162, 164, 172–173, 178, 180, 192, 205, 216, 221, 229, 237, 246
- Motor system, 109, 132, 138, 141, 147, 150–151, 192, 233, 247
- Müller, A., 160–161
- Multidimensional Personality Questionnaire, 108
- Murphy, J., 6, 49
- Murrell, B., 104
- Myerson, J., 90, 100–101, 103–104, 244–245
- Nalmefene, 185, 188–190
- Naltrexone, 184–185, 187–189, 193
- Naor-Ziv, R., 97
- Nash's equilibrium, 71, 230
- Nasqvi, N., 156, 174
- Nathan, P., 194, 216
- National Gambling Impact Study Commission 1999, 190
- National Institute on Alcohol Abuse and Alcoholism's National Epidemiologic Survey on Alcohol and Related Conditions, 193
- Nature–nurture controversy, 7–8
- Nefazadone (Serzone), 188
- Nelson, S., 162, 193, 202
- Neostriatum, 142
- Nestler, E., 190
- Neuroadaptation, 6, 164, 200–201, 207, 221, 226, 229, 233
- Neuroanatomy, 112, 122–123, 125, 131
- Neurobiology, 152, 165, 180–181, 193, 203
- Neurochemical properties, 111–112, 118, 120, 122–124, 131, 136, 144–146, 149–150, 153–155, 161, 168, 172, 186, 201, 203–204, 211, 228, 234
- Neurocomputational model, 10–11, 15, 121, 234
- Neurodynamics, 122–123, 131, 136, 140, 150, 234
- Neuroeconomics (NE), 8, 15, 17–18, 63, 83, 88–89, 93–94, 107, 119–120, 122–124, 130–131, 135, 138, 144–146, 153, 161, 165, 167, 169, 180, 193–194, 201, 204, 210, 214–215, 217–220, 230, 235, 239–240, 246–249
- Neuroimaging, 111, 179, 180, 187, 235–236
- fMRI, 94, 125, 130, 136, 138, 140, 144, 152, 162, 170–171, 173–175, 200, 202–204, 235, 237, 248
- Neuroscience, 42, 83, 108, 115, 118–120, 122, 131, 137, 139, 156, 161–165, 168, 174, 200, 202–204, 211–212, 214, 216–217, 224, 234, 243
- Neurotransmitter, 125, 128, 136–137, 147–148, 154, 160, 176, 181, 188, 241
- Neville, M., 177
- Niesink, R., 136
- Nieuwenhuis, S., 248
- Noë, R., 243–244
- Noradrenergic system, 137, 171, 176
- Nordin, C., 169
- Nower, L., 38–39, 107, 228–230
- Nucleus accumbens (NAcc), 132, 135, 138–139, 142, 146–147, 149–150, 153–157, 167, 169, 186–188, 191, 221, 233
- illustration, 134
- Obsessive-compulsive disorder (OCD), 65, 171–172, 176, 179, 197
- Occipital cortex, 173
- O'Donoghue, T., 88, 93
- Odum, A., 99, 102–103
- Ody, C., 109
- Olanzapine, 185, 189
- Oncken, C., 105
- Operant conditioning, 128
- Opioids (general), 4, 118, 146, 149, 153, 156, 193
- abuse, 103, 152
- peptide, 147
- receptor, 146–147, 188
- receptor antagonist, 181, 184–185, 188, 190
- Opportunity cost, 9, 44–45, 49, 52, 64, 130
- Orbitofrontal cortex (OFC), 9, 132, 144, 152–153, 156, 171, 173
- illustration, 134
- lateral, 175, 235
- medial, 138, 175, 235
- Orsini, C., 191
- Ostaszewski, P., 101
- Pallanti, S., 182, 184
- Pallesen, S., 194
- Paolo Sanna, P., 146
- Parahippocampal region, 173
- Parker, J., 113

- Parkinson's disease, 141, 151–152, 169, 190–192, 228
- Paroxetine (Paxil), 183
- Patak, M., 101
- Pathological gambling (PG), 16, 34–36, 38–39, 41, 52–53, 82–83, 85, 103–104, 107, 110–112, 117, 121, 131, 136, 138–141, 144, 146, 149, 152, 157–158, 161–162, 168–181, 186, 188–193, 195–197, 200–203, 205–211, 216–219, 221, 228–230  
 criterion, 3–4, 205
- Patrick, C., 108
- Patton, J., 106
- Pavlov, Ivan, 128, 142, 197–198
- Peptides, 147
- Perez de Castro, I., 177
- Pergolide, 191
- Perry, J., 99
- Personality, 2, 95, 106–108, 193–194, 219  
 personality disorders, 39, 65, 193
- Personal rules, 67, 69, 71–72, 75, 80–82, 84, 88, 111, 128, 201, 214, 219, 221–223, 225–228, 230–231, 234, 239, 241, 242, 244, 246
- Pesendorfer, W., 94, 236, 238–240, 242–246
- Peterson, J., 115
- Petry, N., 39, 44, 53, 102–105, 107, 193, 195, 206, 208, 211, 217–219  
 Petry's disanalogy, 208
- Phelps, E., 44, 93
- Phenylpiperazine antidepressant, 188
- Phobia, 194, 200
- Physiological response, 82, 112, 144, 169–171, 175, 187, 194, 196–197
- Pickworth, W., 2, 4
- Picoeconomics (PE), 12–15, 41–42, 47–48, 52–53, 62, 65, 67, 75–77, 80, 82–83, 85, 88–89, 91–98, 100, 102–103, 108, 114–120, 122, 127–128, 160–161, 166, 207, 210, 214, 218–221, 227, 230–231, 235, 238–247, 249
- Pietrzak, R., 105
- Pigou, A. C., 24
- Pihl, R., 115
- Pilla, M., 191
- Pitts, W., 9
- Pituitary-adrenal system, 157–158
- Plott, C., 130
- Policy implementation, 14, 22–27, 29, 31, 34–35, 37, 40–41, 45, 65, 82–83, 85, 112, 201, 203, 207, 211, 223, 227
- Pollack, R., 93
- Port, R., 232
- Positron emission tomography (PET), 152
- Posterior parietal cortex (PPC), 173–174
- Posternak, M., 187
- Potenza, M., 150–151, 174–175, 181, 184–185, 193
- Pothos, E., 111
- Poulos, C., 113, 172
- Pramipexole, 190–191
- Predictors of dysfunction, 69, 99, 165–167, 175, 180, 205–207, 230
- Predictor-valuation (PV), 70, 129–130, 139–140, 143–146, 150, 152, 160, 162–163, 166, 169, 178, 205, 207, 210, 225, 247
- Preferences  
 consistency, 48–49, 52, 64–65, 80, 222, 243–244, 246  
 inconsistency, 54, 61, 62, 64, 81, 83, 93, 161, 214, 221, 243  
 reversal, 62, 67, 69, 80, 93, 236, 240, 242  
 theory, 62
- Prefrontal cortex (PFC), 109–112, 131–132, 140, 144, 148, 151, 153, 156, 187, 189, 225, 235, 237  
 illustration, 134  
 inhibition, 230  
 lateral, 235–237  
 motor, 141–142
- Prelec, D., 65
- Prepulse inhibition (PPI), 170
- President Clinton's Committee on the Social and Economic Impact of Pathological Gambling, 33, 43
- Preuschoff, K., 127, 120, 130, 140, 143, 166
- Price sensitization, 78–79, 85
- Priming effect, 112
- Prisoner's dilemma, 70–71, 75
- Problem gambling (PG), 31–35, 37, 52, 118, 201–203, 218, 222–223  
 criterion, 33–36, 39–40
- Psychiatry, 219
- Psychology, 12, 28–29, 43, 51, 94, 165, 170, 243  
 cognitive, 91, 108–109  
 developmental, 175–176, 198  
 neuropsychology, 123  
 personality, 95, 106, 219  
 psychodynamics, 197
- Psychosocial factors, 127, 240
- Pulvirenti, L., 191
- Purdon, C., 198

- Q-learning, 126  
 Quartz, S., 120, 127, 130, 140, 143, 166  
 Quetiapine, 189  
 Quine, W. V., 11, 120  
  
 Rabin, M., 45, 93  
 Rachlin, H., 6, 54–55, 26, 65–66, 73–75, 77–79, 83, 85–87, 93, 100, 180, 208, 219, 221, 230, 246–248  
   relative theory of impulsivity, 180  
 Raineri, A., 100  
 Rate estimation theory (RET), 127  
 Rational decision making, 26–30, 46–48, 54, 57, 62, 80–81, 83, 208–209  
   rational choice theory, 48  
 Read, D., 89–93, 240, 242, 244–245  
 Redish, A., 167  
 Reductionism, 115, 120–121, 161, 210, 231–232, 236–239, 241, 249  
   local reduction, 122, 177–178, 205–206, 211, 217–218, 240  
 Regard, M., 110, 174  
 Regier, D., 180  
 Relapse, 50, 92, 140, 145–146, 151, 155–156, 240–241  
 Repetto, A., 93  
 Rescorla, R., 127  
 Reuter, J., 171, 174  
 Reward, 51–52, 54, 100, 112, 115, 127, 130, 137–140, 143–144, 146, 152, 154, 156, 162, 165, 180, 197, 199, 233, 244  
   bundling, 67–70, 73, 84, 91, 108, 111, 202, 236, 246  
   delayed, 101, 112, 235, 237, 241, 244, 247  
   expectation, 125, 130, 143–444, 147, 153, 175, 199  
   learning, 124, 139, 142–144, 150, 152, 154, 163, 178  
   substance, 156, 159, 209, 228  
 Reward Deficiency Syndrome, 177  
 Reward system, 111, 125, 130–132, 136–137, 139, 141, 145, 147, 153–156, 160, 162–163, 165–166, 168–170, 172, 176, 193–194, 207–208, 210, 216, 219, 221, 225–226, 248  
   dysfunction, 158, 163, 179, 192, 223–224, 228, 230–231  
 Reynolds, B., 101–102, 108, 114  
 Rice, D., 1  
 Richards, J., 113–114  
 Rigotti, N., 227  
  
 Rilling, J., 8  
 Rippens, P., 180  
 Risky decision making, 97, 100, 105, 110–111, 115, 127, 130, 159, 166–167, 175, 193, 207–208, 221, 225, 227, 246, 248  
 Risperidone, 189  
 Robbins, T., 110, 150, 157, 191  
 Roberts, A., 110  
 Robins, L., 180  
 Robinson, I., 139, 141–143, 156  
 Ropinirole, 190–191  
 Rosenkrantz, J., 156  
 Rosenthal, R., 177  
 Ross, D., 10, 12, 14, 18, 29, 48, 62–65, 75, 80–81, 83, 88, 119–121, 204, 219, 231, 237–238, 240, 242–244, 246  
 Roth, A., 45  
 Rotheram-Fuller, E., 98  
 Rougier, N., 109–110  
 Rousseau, F., 107  
 Roy, A., 169  
 Rudgley, R., 224  
 Rugle, L., 110, 174  
 Ryle, G., 11  
  
 Saiz-Ruiz, J., 183  
 Samuelson, P., 58–60, 88  
 Sanabria, F., 127–128  
 Santiesteban, M., 99  
 Sarbin, T., 4  
 Scalar expectancy theory (SET), 127  
 Schelling, T., 62  
 Schizophrenia, 39, 185, 189  
 Schmah, C., 193  
 Schroeder, T., 139, 141–142  
 Schuh, L., 5  
 Schultz, W., 139–141  
 Screening, 36–38, 40, 118, 168, 203  
 Seamans, J., 148, 153–154  
 Seeking behavior, 144, 150, 164, 166, 204, 207–209, 247–248  
 Sejnowski, T., 9, 129  
 Selective serotonin reuptake inhibitors (SSRIs), 181–184, 186–188, 190, 193  
 Self-control, 20, 54, 65–69, 72, 83–85, 92–93, 104, 146, 152, 156, 165, 171–172, 174, 186, 205–206, 219, 224–225, 231, 233, 238–239  
 Self-reinforcement, 155, 164  
 Sellars, W., 11  
 Sensation seeking, 106, 167, 193, 208, 219

- Serotonin (5-HT), 135, 137, 147, 151, 156, 170, 181, 187, 236–247  
 antagonists, 181, 184, 188, 190  
 deficiencies, 171, 186, 189  
 receptor, 186, 189  
 systems, 137, 160, 176, 193, 205–206, 219, 221, 226, 231, 241  
 treatment, 193
- Sertraline (Zoloft), 183
- Sex Addicts Anonymous, 213
- Sexaholics Anonymous, 213
- Sex and Love Addicts Anonymous, 213
- Sexual Addiction Screening Test, 213
- Sexual behavior, 17, 153, 211–217, 221, 224
- Shaffer, H., 105, 162, 193, 202, 218
- Shallice, T., 110
- Sharp, C., 8
- Sharpe, L., 35
- Sherringtonian reflexive response, 154
- Shimamura, A., 109
- Shinohara, K., 169
- Shopping, 160–161, 211–213
- Short-range interests, 63, 71, 115, 180, 230, 233–235, 241–242, 247
- Siegel, E., 74
- Simpson, C., 102, 237
- Situational influence, 83, 112, 115, 152, 176, 180, 213
- Skinner, B. F., 128, 197–198
- Slutske, W., 177, 180
- Smaller sooner reward (SSR), 44, 53, 55–57, 60–61, 65–70, 73, 83–85, 90, 92, 99, 219, 230–231, 233–236
- Smith, L., 232
- Social factors  
 interaction, 77–78, 85, 115, 138, 180, 207, 211–212  
 learning, 159, 225–226, 231, 240  
 norms, 213–214, 223, 231, 233, 244
- Sokoloff, P., 191
- Solomon, H. C., 197–198
- Soochow Gambling Task, 97
- South Oaks Gambling Screen (SOGS), 38–39, 103–104, 107, 118, 168
- Spear, L. P., 175
- Specker, S., 39
- Standard economic theory, 62, 243–244
- Stanford, M., 106
- Stanton, M., 162, 193, 202
- Steel, Z., 107
- Steenbergh, T., 107
- Steketee, J., 148–149, 171
- Stephens, D., 100
- Sterelny, K., 11
- Stewart, D., 115
- Stimulant drugs (general), 118, 146, 148, 155–156, 172  
 abuse, 150, 172
- Stimuli (cues), 139, 155–156, 160, 162–163, 169, 226, 247  
 cocaine, 153–154  
 gambling, 172, 297
- Stinchfield, R., 39
- Stitzer, L., 96
- Stojanov, W., 170
- Stout, J., 152
- Straube, T., 200
- Striatum, 132, 146, 150, 152–153, 169, 174, 237
- Stroop task, 110–111, 152, 174
- Strosahl, K., 198
- Stuck, G., 232
- Subcortical areas, 109, 149–151, 162
- Subpersonal economies, 29, 67, 71, 88–89, 238–240, 242–243, 249
- Substances, 1, 67, 77–78, 80, 82, 148, 151, 159, 163–165, 174, 199, 208–209, 211–212, 222, 228
- Substance use disorders (SUDs), 3, 179–180, 186, 193, 194, 218  
 substance abuse, 1, 13, 16, 43–45, 53, 58, 60, 65, 75, 80, 83, 95, 98–99, 102, 104–105, 117–118, 136, 149, 152–153, 161–162, 170–171, 174, 178, 180–181, 188, 197, 209, 213, 215–216, 220, 224–226, 228–229  
 substance dependency, 2, 3, 39, 65, 76, 94, 96, 140, 144–146, 207, 212, 226, 246
- Substantia nigra pars compacta (SNpc), 132–137, 140–141, 146, 152
- Sugden, R., 81
- Surgeon General's report, 5
- Sutton, R., 125–126, 137, 150–151, 153–154
- Tamminga, C., 190
- Taurus, J., 44
- Taylor, E., 9
- Taylor, J., 150–151, 174–175
- Tellegen, A., 108
- Temporal difference (TD) learning  
 formula, 125–129, 143, 247
- Temporal interval, 51–53, 55, 73, 74–75, 80, 88, 90–91, 93–95, 129, 243
- Temptation, 69, 238–240, 242–243

- Testosterone, 98, 177
- Thalamus, 133, 138, 152, 154, 156, 173, 187  
illustration, 134
- Thelen, E., 232
- Tobacco, 4–6, 107, 118, 147, 149–150, 153,  
160, 162–163, 192, 207, 212, 227  
disordered smokers, 219  
health risks, 209  
smoking, 1, 60–61, 67, 69, 96–99, 101,  
105, 138, 152, 155, 165, 207–208, 221,  
226–227, 231  
smoking cessation, 102, 107–108
- Tobacman, J., 93
- Tolerance, 49–50, 77, 164
- Toneatto, T., 194
- Topamax, 186
- Topiramate, 184
- Tranel, D., 98
- Treatment, 39–41, 158, 178–179, 181, 187,  
192–193, 205, 209, 229, 233  
pharmacology, 16, 119, 144, 146, 149,  
161–165, 167, 178–179, 181, 189–190,  
192–193, 197, 201, 203–204, 216–217,  
219, 221  
pharmacology table, 181–187  
psychotherapy, 183, 192, 194, 197, 209,  
217, 229
- Trout, J., 195–196
- Tucker, J., 92, 180
- Tulving, E., 109
- Turnbull, O., 98
- UPPS Impulsive Behavior Scale, 106–107
- Valenstein, E., 139
- Valuation, 8, 9, 15, 29, 53–54, 74–75, 108,  
124–125, 127, 129–130, 142–144, 159–  
160, 165, 199, 215  
equation and graph, 56
- Vander Bilt, J., 105, 218
- Van der Linden, M., 107
- van Fraassen, B., 63
- van Gelder, T., 232
- Van Honk, J., 98
- van Hoof, J., 243–244
- Vazire, S., 107, 193
- Ventral striatum (VS), 139, 154, 173–175,  
235  
illustration, 134
- Ventral tegmental area (VTA), 132–137,  
139–141, 146, 152, 157, 171, 230, 247  
illustration, 134
- Ventrolateral orbital, 163
- Ventromedial PFC (VMPFC), 110, 133,  
148–150, 153–154, 171–174, 245, 248
- Visceral factors, 91–94, 240–242, 244–246
- Vitaro, F., 99
- Volkow, N., 153–156, 165
- Vuchinich, R., 6, 92, 102, 180, 237
- Wager, T., 187
- Wagner, A., 4, 127
- Walton, R., 177
- Warner, J., 4
- Wells, A., 198–199
- Wexler, B., 226
- Wheeler, H., 227
- Whewell, W., 222
- Whiteside, S., 106
- Whitlow, C., 96
- Wilbarger, J., 113
- Williams, J., 9
- Willoughby, A., 248
- Wilson, M., 113, 198
- Winkielman, P., 113
- Winston, G., 99
- Winters, K., 39, 175
- Wisconsin Card Sorting Task (WCST),  
109–110
- Wise, R., 157, 163–166
- Withdrawal, 117–118, 145, 154–156, 161,  
164, 240–241
- Wittgenstein, L., 11
- Wolpe, J., 197–198
- World Health Organization (WHO), 2
- Wynne, H., 39
- Yang, C., 148, 153–154
- Zack, M., 172
- Zajonc, R., 112
- Zimmerman, M., 183, 187
- Zink, C., 144
- Ziprasidone, 189

